Product Images Sumatriptan Succinate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Sumatriptan Succinate NDC 70518-1183 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

This is a description of a medication called Sumatriptan Succinate. It is an RX ONLY medication with a 50mg dose in a tablet form. The medication was manufactured by Sun Pharma in Cranbury, NJ and the repackaging was done by RemedyRepack. The NDC # for this medication is 70518-1182-00 and the expiration date and LOT # are not available. The medication should be stored between 20-25°C (88-77°F) and kept out of reach of children. The directions for use can be found in the package insert.*

chemical-structure - chemical structure

chemical-structure - chemical structure

Sumatriptan-figure-1 - sumatriptan figure 1

Sumatriptan-figure-1 - sumatriptan figure 1

This is a figure that shows the estimated probability of achieving initial headache response within 4 hours of treatment with oral sumatriptan. The data is based on pooled results from three clinical trials. The figure shows different probabilities of response after taking different doses of sumatriptan (25mg, 50mg, and 100mg) compared to a placebo. The probability of response is shown over time, up to 240 minutes from the initial dose.*

Sumatriptan-figure-2 - sumatriptan figure 2

Sumatriptan-figure-2 - sumatriptan figure 2

This is a figure that shows the probability of patients taking a second dose of Sumatriptan Succinate Tablets or other medication to treat migraine over the 24 hours following the initial dose of study treatment in pooled trials 1, 2, and 3. The plot is a Kaplan-Meier plot based on data obtained in the 3 clinical controlled trials providing evidence of efficacy, with patients not using additional treatments censored to 24 hours. The plot also includes patients who had no response to the initial dose. No remedication was allowed within 2 hours postdose.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.